CinCor Pharma, Inc. financial data

Location
230 Third Ave., 6 Th Floor, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2022 - Nov 3, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.26K %
Return On Equity -33 %
Return On Assets -27.2 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43.8M shares
Common Stock, Shares, Outstanding 43.8M shares
Common Stock, Value, Issued 438 USD
Weighted Average Number of Shares Outstanding, Basic 40.8M shares +2246%
Weighted Average Number of Shares Outstanding, Diluted 40.8M shares +2246%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 53.9M USD +281%
General and Administrative Expense 28.6M USD +48.5%
Operating Income (Loss) -82.5M USD -189%
Nonoperating Income (Expense) 8.53M USD -195%
Net Income (Loss) Attributable to Parent -88.1M USD -132%
Earnings Per Share, Basic -0.51 USD/shares +90.2%
Earnings Per Share, Diluted -0.51 USD/shares +90.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 293M USD
Assets, Current 529M USD
Property, Plant and Equipment, Net 99.7K USD
Assets 529M USD
Accounts Payable, Current 2.59M USD
Employee-related Liabilities, Current 0 USD
Accrued Liabilities, Current 2.48M USD
Liabilities, Current 10.2M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -883K USD
Retained Earnings (Accumulated Deficit) -136M USD
Stockholders' Equity Attributable to Parent 519M USD
Liabilities and Equity 529M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.7M USD -207%
Net Cash Provided by (Used in) Financing Activities 196M USD
Net Cash Provided by (Used in) Investing Activities -150M USD
Common Stock, Shares Authorized 95M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 293M USD +106%
Cash and Cash Equivalents, Period Increase (Decrease) 28M USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -21.1M USD -134%
Additional Paid in Capital 656M USD